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ABSTRACT
Human microbiota, majority presents in human gastrointestinal tract, plays crucial role in body physiological 
functions, such as immune system. Human immunodeficiency virus (HIV) infection impairs gut barrier and alter 
the microbiota ecosystem, called dysbiosis. Several studies showed different composition of gut microbiota between 
healthy individual and HIV patient. Moreover, different phase of HIV infections had their own characteristic of 
gut microbiota. Antiretroviral treatment might improve the CD4 level, however, it inconsistently restore the gut 
ecosystem. Some studies in prebiotic and probiotic revealed the potential beneficial effect in gut microbiota. 
Probiotic might inhibit mucosal invasion, improve intestinal mechanical barrier integrity, reduce microbial 
translocation, restore mucosal immune function, counteract local inflammation and lower systemic inflammation.
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ABSTRAK
Microbiota pada manusia yang mayoritas terdapat pada saluran cerna memainkan peranan penting pada 
fungsi fisiologis tubuh seperti sistem imun. Human immunodeficiency virus (HIV) merusak sawar saluran cerna 
dan merubah ekosistem mikrobiota, yang disebut disbiosis. Beberapa studi menunjukkan perbedaan susunan 
mikrobiota usus antara orang sehat dengan pasien HIV. Bahkan tiap fase infeksi HIV memiliki karakteristik 
mikrobiota usus tersendiri. Terapi antiretrovirus dapat memperbaiki kadar CD4, tetapi tidak memperbaiki 
ekosistem saluran cerna secara konsisten. Beberapa penelitian pada prebiotik dan probiotik memperlihatkan 
potensi yang menguntungkan terhadap mikrobiota saluran cerna. Probiotik menghambat invasi mukosa, 
memperbaikan integritas sawar mekanik usus, mengurangi translokasi mikroba, memperbaikI sistem imun 
mukosa, menurunkan peradangan local dan sistemik.
Kata kunci: mikrobiota saluran cerna, human immunodeficiency virus, disbiosis, probiotik 
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INTRODUCTION
Studies of human microbiome are subject of current 
great interest nowadays. More than 90% of the cells 
within and on the human body are of microbial origin. 
It is estimated over 1014 microorganisms resides in 
human body. They are collectively called microbiota, 
the genomes of which act together as a living system 
known as microbiome. About 99% of the microbiota 
is present in the human gastrointestinal tract. The gut 
microbiota consists of large, diverse collection of 
trillions of bacteria, archaea, eukarya, and viruses. It 
contributes to the development and maintenance of 
physiological responses within the host. It also plays 
crucial role in maintaining intestinal homeostasis, 
mucosal barrier system, regulation of innate and 
adaptive immune system.1-7 
Chronic inflammation and systemic illness 
such as inflammatory bowel disease, obesity, 
cardiovascular diseases affect the composition of the 
intestinal microbiota, resulting dysbiosis.8-11 Human 
immunodeficiency virus (HIV) infection impairs gut 
barrier and alter the composition of microbiota. Gori 
et al firstly observed high prevalence of opportunistic 
pathogen microorganism (Pseudomonas aeruginosa, 
Candida albicans) and lower level of Bifidobacteria 
and Lactobacilli in HIV patient.12 This finding has 
attracted attention and research dedicated to investigate 
the relationship is currently growing. Moreover, it has 
been proposed as a prospective novel therapeutic target 
in HIV patients.
This paper aimed to review the impact of HIV 
infection in intestinal microbiota during various 
HIV infection course ie., early infection, chronic 
infection and after anti retroviral treatment. We also 
discuss potentials clinical application of microbiota 
restorations in daily practice.
Microbiota in Human Intestine
Characterization of the microbiome profile in healthy 
intestine is an important initial step in understanding 
the role of microbiome. In recent years, new “omic” 
technologies have facilitated the analysis of human 
gut microbiome which was overlooked previously. 
Current studies in gut microbiota use 16S rRNA 
based sequencing of bacterial gene and bioinformatic 
analysis. Almost all studies have exclusively focused 
on the bacterial component of the gut microbiome. It 
is estimated that over 35,000 bacterial species reside 
in human gastrointestinal tract. There is a significant 
difference in genus and number of bacteria residing in 
human gastrointestinal tract, starting from esophagus 
to colon. Large intestine harbors over 70% of all 
microbes in human body, predominantly by Firmicutes 
and bacteroides phyla. Moreover, there is also an 
axial difference of genera in human intestine, existing 
from luminal, mainly composed of Bifidobacterium, 
Streptococcus, Enterobacteriaceae, Enterococcus, 
Ruminococcus, to mucosal surface, mainly composed 
of Clostridium, Lactobacillus, Akkermansia of human 
intestine. Gut microbiota plays important roles such 
as nutrient metabolism by fermenting carbohydrates 
and indigestible oligosaccharide which result in the 
synthesis of short chain fatty acid (butyrate, propionate, 
acetate) as a source of energy for gut mucosa. It also 
involve in production of vitamin K, several components 
of vitamin B, conjugated linoleic acid, citric acid, 
pyruvic acid, and demonstrates benefit in lipid 
metabolism by influencing lipoprotein lipase activity 
in adipocytes and lipid hydrolysis. Gut microbiota 
contribute to host innate and adaptive immune system 
through gut-associated lymphoid tissue (GALT), 
effector and regulatory T cells, IgA producing plasma 
cells, dendritic and macrophage cells. Furthermore, 
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Figure 1. Differences in rectal mucosal microbiota between healthy subjects and HIV-positive subjects 
(Modified from McHardy et al)22  
 
Gut Microbiota in Early Phases of HIV Infection 
 There is a rapid viral replication, high immune response, and massive destruction of 
immune system in early phases of HIV infection. Gori et al firstly demonstrated increase in 
opportunistic pathogen in fecal sampels: Candida albicans (10,000-fold higher in the HIV-positive 
subjects compared to healthy subjects) and Pseudomonas aeruginosa (10-fold increase in HIV-
positive subjects compared to healthy subjects). In comparison with healthy subjects, fecal 
bifidobacteria and lactobacilli were decreased in HIV-positive subjects.12 Study by Vujkovic-
Cvijin et al showed decreased in Enterobacteriaceae family and Bacteroidia class in untreated HIV 
patient.23
Gut Microbiota in Chronic Human Immunodeficiency Virus (HIV) Infection 
 Observation study by Dillon et al showed different mucosal bacterial composition between 
chronic HIV-infected subjects and healthy subjects. Although both groups were dominated by 
Firmicutes, Bacteroidetes, Proteobacteria phyla, there was a significant lower median amount of 
Firmicutes (p = 0.03) and higher median abundance of Proteobacteria (p = 0.03) in HIV-infected 
subjects (Figure 2). Relative abundance of Proteobacteria phylum in HIV infection relates with 
production of hydrogen sulfide compounds and epithelial inflammation by Desulfovirbrio, 
increase production of IL-8 and lipopolysaccharide by Acinetobacter. Comparisons of bacteria at 
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gut microbiota helps maintaining the integrity of 
gastrointestinal structure and function.2,6,11,13-19 
Gut Microbiota in Human Immunodeficiency Virus 
(HIV) Infection
Gut microbiota is a critical factor in the development 
and maintenance of physiological immune response 
within the host. Human gastrointestinal tract, 
especially GALT, is the major site of HIV replication. 
Moreover, around 60% of human CD4+ T cells reside 
in GALT. The HIV infection results in unfavorable 
pathologic manifestations: it breakdowns gut barrier 
by enhancing epithelial permeability and decrease 
repair function, increase production of inflammatory 
cytokines, disrupts the balance between gut bacteria 
and immunity, increases translocation of microbes, 
and shifts the composition of gut microbiota to pro-
inflammatory or pathogenic dominant population.5,20 
This, results in disturbance of gut microbiota 
ecosystem, called dysbiosis.14,19,21 Study by Dubourg 
et al showed decrease in local environment diversity, 
i.e. alpha diversity due to HIV infection (p = 0.00078).3 
McHardy demonstrated numerous different of rectal 
mucosal microbial taxa between healthy subjects and 
HIV-positive subjects (Figure 1).22 
Gut Microbiota in Early Phases of HIV Infection
There is a rapid viral replication, high immune 
response, and massive destruction of immune system 
in early phases of HIV infection. Gori et al firstly 
demonstrated increase in opportunistic pathogen in 
fecal sampels: Candida albicans (10,000-fold higher 
in the HIV-positive subjects compared to healthy 
subjects) and Pseudomonas aeruginosa (10-fold 
increase in HIV-positive subjects compared to healthy 
subjects). In comparison with healthy subjects, fecal 
bifidobacteria and lactobacilli were decreased in HIV-
positive subjects.12 Study by Vujkovic-Cvijin et al 
showed decreased in Enterobacteriaceae family and 
Bacteroidia class in untreated HIV patient.23 
Gut Microbiota in Chronic Human Immunodeficiency 
Virus (HIV) Infection
Observation study by Dillon et al showed different 
mucosal bacterial composition between chronic HIV-
infected subjects and healthy subjects. Although both 
groups were dominated by Firmicutes, Bacteroidetes, 
Proteobacteria phyla, there was a significant lower 
median amount of Firmicutes (p = 0.03) and higher 
median abundance of Proteobacteria (p = 0.03) in 
HIV-infected subjects (Figure 2). Relative abundance 
of Proteobacteria phylum in HIV infection relates 
with production of hydrogen sulfide compounds and 
epithelial inflammation by Desulfovirbrio, increase 
production of IL-8 and lipopolysaccharide by 
Acinetobacter. Comparisons of bacteria at the family 
level showed differences in overall relative abundances 
(p = 0.02). Prevotellaceae was significantly higher (p 
= 0.03) and Lachnospiraceae, Christensenellaceae, 
Ruminococcaceae, Bacteroidaceae were significantly 
lower in HIV-infected subjects (p = 0.09, p = 0.04, p = 
0.04, p = 0.04, respectively) (Figure 3). There was also 
significant difference at genera level (p = 0.009), with 
a decrease in Bacteroides: Prevotella ratio (Figure 4).24 
Observational study by Nowak et al showed reduced in 
gut microbiota alpha diversity (lower Shannon index) 
in viremic HIV subjects which correlated with CD4+ 
T-cell count (p = 0.01).25 Patients with CD4 < 200 had 
significantly decreased in bacterial richness, bacterial 
phylogenetic diversity compared to patients with CD4 
> 200.26 A case control study by Dubourg et al also 
showed reduced in alpha diversity in HIV-infected 
subjects. There was an increase in aerobic bacteria 
(Enterobacteriaceae and Enterococcaceae family) 
and decrease in anaerobic bacteria (Ruminococcaceae 
family). This, associated with difference in chemokines, 
T-cell activation marker finding between HIV-infected 
subjects and healthy subjects.3 
Figure 2. Comparison of the relative abundance of the Bacteroidetes, Firmicutes, Proteobacteria and other phyla between healthy 
subjects and HIV-infected subjects24
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Impact of Antiretroviral Treatment in Gut Microbiota
Studies on the short-term and long-term impact 
of antiretroviral treatment on the gut microbiota have 
convincingly demonstrated that antiretroviral treatment 
is unable to consistently restore human gut health. A 
study of rectal mucosal microbiota by McHardy et 
al demonstrated incompletely improvement in rectal 
mucosal microbiota diversity after antiretroviral 
treatment.22 In contrast, the reduced in diversity was 
not restored by antiretroviral treatment according to the 
study by Dubourg.3 In a stool gene sequencing study 
by Lozupone et al relatively short term antiretroviral 
treatment (6.7-8.5 months) insufficiently restored the 
microbiota composition; however, longer duration of 
treatment might not predict complete restoration.27 
Further study with greater subjects by Lozupone et 
al demonstrated different response to antiretroviral 
treatment between bacterial taxas. The increase 
abundance of Prevotella, Prevotellaceae in untreated 
HIV-positive subjects did not decrease significantly 
toward level in healthy subjects after antiretroviral 
treatment, but Peptococcus was significantly decrease 
with antiretroviral treatment. Bacteroides and 
Odoribacter were remain at low prevalence in spite of 
antiretroviral treatment.28 
Probiotics as Potential Therapeutic Approach
Although the invention of antiretroviral drugs 
have successfully suppressed viral load and improved 
CD4 counts, most studies still inconsistently showed 
restoration of gut microbiota in HIV-treated subjects. 
This, commonly associated with persistence of 
chronic inflammation, activation of immune system, 
bacterial translocation. Probiotics are non-pathogen 
microorganisms, which in adequate amounts, 
confers health benefit on the host. Prebiotics are 
natural or processed non-digestible food, generally 
oligosaccharides, which also have benefit on the 
host. Many efforts are currently done in this field to 
assess their potential role in modifying, restoring gut 
microbiota and reducing inflammatory process.29,30 
Several studies reported beneficial effect of probiotics 
supplementation. Gori et al in a pilot randomized, 
placebo-controlled double blind study demonstrated 
dietary prebiotic supplementation significantly 
increased bifidobacterium and decreased pathogenic 
clostridium.31 A pilot study by Scagnolari et al reported 
decreased expression of indolamine-2,3-dioxygenase 
(IDO), an enzyme associated with neuronal toxicity 
and neurocognitive disorders, in GALT after probiotic 
supplementation in antiretroviral-treated HIV infected 
patients.32 d’Ettorre et al showed increased in Th1 
cell in GALT (p = 0.005), lower in intraepithelial 
lymphocytes at cecum, ileum, transverse, descending 
Figure 3. Comparison of the average relative abundance of the top 10 most abundant bacterial families24
Figure 4. Significant decrease in Bacteroides: Prevotella ratio in HIV subjects24
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy42
Rudi Wisaksana, Guntur Darmawan, Nenny Agustanti, Dolvy Girawan
colon (p = 0.049, p = 0.027, p = 0.004, p = 0.002, 
respectively), lower frequencies of CD4+ and CD8+ 
T-cells expressing alternately CD38 or HLA-DR 
(CD4+ cells: p = 0.005 and p = 0.005, respectively; 
CD8+ cells: p = 0.037 and p = 0.005, respectively) after 
probiotic supplementation.33 A 3-month double-blind 
placebo-controlled trial of Bacillus coagulans by Yang 
et al reported significant increase in the percentage of 
blood CD4+ (+ 2.8% vs. -1.8%; p = 0.0018) in subjects 
with HIV- infection on optimal antiretroviral treatment. 
However, the pro inflammatory biomarkers did not 
change significantly.34 Moreover, a retrospective 
observational study by Irvine et al in Tanzania revealed 
an increased in CD4+ 0.17 cells/mL/day (95% CI: 
0.01-0.34; p = 0.04) in Lactobacillus rhamnosus 
yogurt consumer after adjusting for length of time 
using antiretroviral medication.35 Several mechanisms 
are proposed to explain the benefit effect of probiotic. 
Probiotic can inhibit mucosal invasion, improve 
intestinal mechanical barrier integrity, reduce microbial 
translocation, restore mucosal immune function, 
counteract local inflammation and lower systemic 
iinflammation, stimulate production antimicrobial 
substances, increase intestinal immunoglobulin.5,20,36,37 
CONCLUSION
HIV infection results in unfavorable change of 
human gut microbiota composition. The invention 
of antiretroviral contributes significantly in HIV 
treatment; however, it inconsistently restores gut 
microbiota composition. Probiotic, non-pathogen 
microorganisms, might play a promising role in 
improving microbiota composition.
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